.
Covifor will be readily available in 100 mg vial (injectable) which needs to be administered intravenously in a medical facility setting under the guidance of a healthcare professional.
Drugmaker Hetero has received the Drug Controller-General of India (DCGI) approval to produce and offer its generic variation of Gilead’s Remdesivir for the treatment of COVID-19 clients in the country.
The generic version will be marketed under the brand name ‘Covifor’ in India, Hetero stated about the product, that is being produced at its center in Hyderabad.
Combating COVID-19
Chairman of Hetero Group of Companies B. Partha Saradhi Reddy stated the approval of Covifor (Remdesivir), in the middle of the increasing COVID-19 cases in the country, can show to be a game-changer offered the favorable medical results.
” Backed by strong backward integration abilities, we can make sure that the product is right away made